Joined Nov 11, 2007
31,929 Blog Posts

Teva First-Quarter Profit Slides on Provigil, Generics

Teva Pharmaceutical Industries Ltd. (TEVA)’s first-quarter profit fell 26 percent as a branded drug lost patent protection and opportunities diminished to introduce new generic medicines.

Earnings excluding some costs declined to $960 million, or $1.12 a share, from $1.3 billion, or $1.47, a year earlier, the Petach Tikva, Israel-based company said in a statement today. Profit beat the average estimate of $1.11 a share from 20 analysts surveyed by Bloomberg.

Teva’s branded-drug sales dropped as Provigil, a sleep- disorder medicine it got in the $6.5 billion acquisition of Cephalon Inc. in 2011, lost patent protection last year. Sales of generics were higher in last year’s first quarter as Teva began selling seven new products and benefited from a partnership with Ranbaxy Laboratories Ltd. for copies of Pfizer Inc.’s Lipitor.

Revenue from Copaxone, the branded multiple-sclerosis treatment that is Teva’s best-selling product, increased 17 percent in the quarter to $1.1 billion as Teva boosted the price of the injection. Copaxone faces new competition from Biogen Idec Inc.’s Tecfidera, which grabbed an 8 percent share of the MS pill market in the week ended April 19, according to Bloomberg Industries.

Feedback from doctors suggests some Tecfidera patients are switching from Copaxone, according to Marko Kozul, an analyst with Leerink Swann & Co.

Levin’s Forecast…”

Full report

If you enjoy the content at iBankCoin, please follow us on Twitter